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Abstract
Thalidomide is an anti-inflammatory and an anti-angiogenesis drug that is being used around the world for a variety of malignant and inflammatory diseases. Is it justified to continue prescribing and developing thalidomide given the discovery of many
well-known side effects including catastrophic birth defects? To answer this question, this paper will discuss the pharmacology
and history of thalidomide, as well as many of its proposed mechanisms of action. The medical indications for the current use of
thalidomide as well as for several newer and more potent derivatives are mentioned for their therapeutic results, as well as their
adverse side effects.
Introduction to Thalidomide
“Thalidomide remains, arguably, the greatest disaster in medical
history” (Greener, 2011). Thalidomide was introduced in 1957
by a German pharmaceutical company as a sedative and hypnotic drug. It was also widely used in several countries to alleviate
morning sickness in early pregnancy. It was sold in more than
forty-six countries without any testing for teratogenicity, as was
common practice for new drugs at that time. More than 10,000
children around the world developed severe birth defects, especially shortening or absence of limbs. There was also an increase
in miscarriages and infant mortality. Remarkably, the United States
Food and Drug Administration did not approve sale of thalidomide despite five requests from manufacturers. As a result, only
seventeen babies were affected in the United States, probably
from thalidomide purchased in Canada (Huang, et. al. 2008).
By 1961 production and distribution of thalidomide were
banned worldwide. Due to the risk of teratogenicity, almost no
research into the use of thalidomide took place for the next
decade. The first new indication for thalidomide was in treating
a complication of leprosy known as erythema nodosum leprosum (ENL) (Sharma, et. al. 2007). Beginning in 1967, anecdotal
reports of the use of thalidomide in cancer treatment began to
be published. Some of the diseases treated were astrocytoma,
multiple-myeloma, chronic lymphocytic leukemia, and malignant
melanoma. New research is being done to investigate the mechanism of action of this class of immunomodulatory drugs in various
malignancies and in non-malignant conditions such as Alzheimer’s
Disease and persistent erythema multiforme (He, et. al. 2013).

Methods
Articles and studies researched in this paper were obtained
through the EBSCO and ProQuest databases with access provided by the Touro College Library. Additional research articles
were obtained through the National Center for Biotechnology
Information (NCBI) website and the Jackson Laboratory website. Images and diagrams that are used throughout the paper
were obtained from the research articles cited.

Chemical Analysis
Thalidomide is a racemic glutamic acid analogue also known as
[+] alpha-[N-phthalidimo]-glutarimide. It consists of two linked
rings: a glutamic ring and a phthalic ring. Because it contains a
chiral carbon the molecule is unstable and can switch back and

forth between two enantiomers which are mirror images of
each other. This reaction takes place rapidly in water or body
fluids. While only one state, the S-enantiomer is thought to be
teratogenic, the safer state, the R-enantiomer, is not stable and
cannot be preserved in the body. (Bartlett, et. al. 2004)
Thalidomide has traditionally been synthesized by a multistep process which uses expensive ingredients and produces a
very low yield. A recent research study by chemists at Stockton
University in New Jersey reports on a new rapid synthesis of
thalidomide and its analogs using easily obtained reagents which
rapidly interact with the assistance of a microwave. It produces
relatively high yields. The reaction of the corresponding anhydrides using DMAP (4-N, N- dimethylaminopyridine) as a base
catalyst takes place in ten minutes at 150 degrees Celsius. The
chemists developing this new method of production describe
their innovation as a, “novel green one-pot synthetic technique.”
(Benjamin, et. al. 2017)

Pharmacology
Thalidomide has an active half-life of 8 to 12 hours. It is broken down by hydrolysis in tissue fluids and metabolized by the
liver using the cytochrome p450 system. Although it is absorbed
slowly, it has a high oral bioavailability.The plasma concentration
peaks after at least two hours. Little drug is bound to protein in
the plasma.The average elimination half-life of both enantiomers
is five hours. (Vargesson, et. al. 2015)
According the British Columbia Cancer Drug Manual accessed online, high fat meals increase the time to peak concentration. Thalidomide is distributed mostly in the internal
organs such as the gastro-intestinal tract, liver and kidneys. It
is found to cross the blood brain barrier and is also found in
the ejaculate.
In 2004, a new derivative of thalidomide was introduced for
treatment of multiple myeloma. Lenalidomide, under the trade
name Revlimid is considerably more potent than thalidomide.
It has an added amino group at position 4 of the phthaloyl
ring and removal of a carbonyl group from the phthaloyl ring.
Pomalidomide (3-aminothalidomide) was the second thalidomide analog to be used in treating multiple myeloma. It is even
more potent than the analogs before it. A third thalidomide
analog, Apremilast is now showing effectiveness as an oral treatment for psoriasis and psoriatic arthritis. (Bartlett, et. al. 2004)
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Mechanism of Action: Innate immunity: Effects
on Epidermal Regeneration, Soluble Mediators,
and Natural Killer Cells
Studies of epidermal regeneration have shown that thalidomide
increases human keratinocytes migration and propagation.
Testing was done with a motility assay and thymidine incorporation assays to better understand how thalidomide promotes
this proliferation. In addition, the chemokine IL-8 that promotes
migration of neutrophils and keratinocytes significantly increases with thalidomide treatment. Because of this, researchers have
theorized that the mechanism with which thalidomide aids in
wound healing is by promoting keratinocyte production and
movement. This may be useful in explaining its ability to treat
ulcerative diseases, such as Behcet’s (a rare disorder causing inflammation in blood vessels with symptoms that include mouth
and genital sores, inflamed eyes, and rashes) and aphthous stomatitis (shallow sores inside the mouth or at the base of the
gums that make it hard to eat or talk) (Paravar & Lee, 2008).
The exact mechanism of thalidomide’s anti-inflammatory
action via soluble immune mediators is still being investigated.
However, researchers have linked thalidomide’s anti-inflammatory action to its ability to speed up the degradation of messenger RNA in blood cells.These effects have been analyzed in both
human monocytes and mouse macrophages (Paravar, Lee, 2008).
By reducing the half-life of the messenger RNA coding for
TNF-alpha, (Tumor Necrosis Factor) it in turn reduces the
blood serum level of TNF-alpha.TNF-alpha is a cell signaling protein (cytokine) involved in systemic inflammation. By reducing
TNF-alpha, thalidomide is an effective treatment for inflammatory diseases such as erythema nodosum leprosum (ENL) and
lupus erythematosus (LE). Many studies have been performed
that confirm this reduction of TNF-alpha. For example, 48-68%
of patients with ENL have a reduction of TNF-alpha in the
serum from their pretreatment levels.Tuberculosis patients also
show reduced levels in in-vitro and in-vivo studies and patients
gained a significant amount of weight while on the medication.
HIV-1 patients also had reduced TNF-alpha levels while under
treatment with thalidomide. A further confirmation comes from
studies using rodent models of pancreatitis in which thalidomide was seen to have similar effects (He, et. al. 2013).
Another proposed mechanism of action involves thalidomide’s effects on Natural Killer (NK) cells which are vital in
destroying tumor cells, intracellular pathogens, and cells infected by viruses. Using in-vitro studies, thalidomide has been
observed to enhance NK-cell-mediated lysis of cancerous cells.
This was demonstrated in a study that co-cultured NK cells
with the same patient’s cancerous cells. Additionally, thalidomide
increases the secretion of NK cell activators such as IL-12 and
specifically induces NK cell antitumor responses. In an in vivo
study, the number of NK cells in a multiple myeloma patient
were increased with thalidomide therapy. The results of these
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studies indicate that thalidomide’s ability to enhance NK-cells
is the mechanism by which it aids in the treatment of multiple
myeloma (Paravar, Lee, 2008).

Adaptive immunity: B Cell Antibody Suppression,
T Cell Stimulation
Thalidomide suppresses B cell antibody formation in studies
primarily using New Zealand Black (NZB) and Murphy Roths
Large (MRL) mice.These strains were chosen because they have
a genetic predisposition to autoimmune disorders (The Jackson
Laboratory Website, updated 2018). Thalidomide inhibits the
usually increased production of splenic IgM in NZB mice and
splenic and lymph node IgG1 in MRL mice. In clinical studies,
leprosy patients receiving thalidomide and dapsone treatment
had lower serum IgM levels than patients receiving dapsone
alone. The combination of these studies suggests that thalidomide’s action may be based on its downregulatory effects on
antibody production (Paravar & Lee, 2008).
Thalidomide was shown to be able to co-stimulate T cells
once they were already partially activated by the T cell receptor.
Co-stimulation is an important mechanism for immune defense.
A second signal is sent to naïve T cells which facilitates their initiation and further generation of an antigen-specific effector response. The co-stimulatory effect of thalidomide can be used as
an immunological adjuvant, that is, it can enhance the response
to tumor antigens in cancer patients (Bartlett, et. al. 2004).

Reduction of Tumorigenesis: Apoptosis and
Restriction of Tumor Growth, and Antiangiogenic
Activity
Tumors grow and expand due to their ability to evade apoptosis. In studies, thalidomide has induced apoptosis (G1 growth
arrest) in human cancerous cells. It has also been shown to
decrease the expression of the apoptosis-suppressing protein
Bcl-2 in blood and bone marrow of patients with multiple myeloma. Another mechanism proposed is thalidomide’s ability to
induce monocyte apoptosis by involving the cytochrome c-dependent pathway. (Cytochrome c is known for its role in the
mitochondria as a key contributor in ATP synthesis. In our case,
we are more interested in thalidomide’s stimulation of cytochrome c’s other effect which is triggered when a cell receives
an apoptotic stimulus. The cytochrome c is then released into
the cytosol and triggers programmed cell death through apoptosis) (Paravar & Lee, 2008).
In 1971, Dr. Judah Folkman of Harvard Medical School formulated his hypothesis that tumor growth depends on angiogenesis, the formation of new blood cells in the malignant tissue.
Thalidomide, as mentioned above, inhibits limb bud formation
in the embryo. This led to the idea that the teratogenic and
antiangiogenic actions may be related.
Dr. Folkman made the groundbreaking discovery that tumor
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growth and angiogenesis were related when he was working on
testing the efficacy of hemoglobin solutions as a substitute for
blood transfusions. As a part of this study he injected isolated
organs with mouse melanoma cells. He found that the tumors
could not grow and spread in the isolated perfused organs, but
when they transplanted these same tumor cells into mice, they
were quickly vascularized and grew larger. After conducting
more research trials to prove his hypothesis, Dr. Folkman published an article in the New England Journal of Medicine that
stated that tumor growth depends on angiogenesis and that inhibiting angiogenesis can be used to treat certain cancers. From
1980 to 2005 Dr. Folkman’s lab worked on testing twelve angiogenic inhibitors including interferon alpha, fumagillin, endostatin
and, notably, thalidomide (Ribatti, 2008).
Angiogenesis, the development of new blood vessels, is vital to
the growth and spreading of cancerous tumors. The cancer degrades basement membranes and extracellular matrix and brings
endothelial cells towards an angiogenic stimulus. It also involves
pericytes and smooth muscles cells as well. Various growth factors are also needed to form new blood vessels from preexisting
micro vessels. These growth factors include vascular endothelial
growth factor (VEGF), basic fibroblast growth factor (bFGF), and
platelet-derived growth factor (PDGF) (Fialho, et. al. 2013).
One proposed mechanism for thalidomide’s antiangiogenic
effect is its ability to inhibit VEGF and bFGF production, which
thereby inhibits vessel growth. Studies using human endothelial
cells showed that thalidomide inhibits VEFG secretion and cell
migration and lowers the total number of capillaries. In studies
using chicken embryonic chorioallantoic membrane (CAM) thalidomide inhibited VEGF and bFGF induced vessel growth. In one
trial done by the Department of Cellular and Molecular Biology
and Pathogenic Agents of the University of Sao Paulo, twelve
CAMs from chicken eggs were incubated with thalidomide implants and analyzed after two days to review the percentage of
vessel deterioration. The results showed significant regression
of vessels in CAM that had thalidomide or thalidomide-loaded
implants as compared to the negative control (NC) group and
an implant not containing any drug (Fialho, et. al. 2013).
Another study proposed that thalidomide inhibits endothelial
cell proliferation by inhibiting the binding of the SP-1 transcription factor, which has many binding sites on the VEGF promoter.
This protein usually binds to the VEGF promoter to initiate and
activate the transcription of the gene directly. When its binding
is inhibited, it causes less VEGF to be produced and therefore
limits the cells’ growth (Yabu, et. al. 2005).
A third mechanism of action being researched is thalidomide’s
ability to suppress the VEGF gene by downregulating the VEGF
receptors Flk-1 and neuropilin-1. By reducing the productivity of the VEGF receptors, thalidomide lessens the effects of
the vascular endothelial growth factor in general. This causes
less signals for angiogenesis to be sent, so the body forms less

vasculature. With a smaller supply of blood, the growing limbs
do not receive enough oxygen and nutrients, and they subsequently do not grow properly and result in under developed or
malformed limbs (Yabu, et. al. 2005).
A study done using zebrafish embryos and Human Umbilical
Vein Cells (HUVEC) showed promising results in this area. The
thalidomide treated embryo was shorter in length than the control. In addition, the lumens of the dorsal artery and posterior
cardinal vein were clearly seen (with hematoxylin and eosin
staining) in the control but were so reduced in the embryo
treated with thalidomide that they were barely visible (Yabu,
et. al. 2005).

Teratogenesis
Over the past fifty years, many separate models for thalidomide
embryopathy have been proposed, however a full understanding of its mechanism of action is still incomplete. The proposed
theories are not necessarily mutually exclusive.And it is possible
that multiple mechanisms of action are each involved to some
extent. Additional theories include nerve toxicity, inhibition of
cell adhesion molecules and effects on chondrogenesis.
One breakthrough discovery revealed that Cereblon (CRBN),
a protein encoded by the CRBN gene, may be the primary target for binding by thalidomide. The authors found that thalidomide binds directly to CRBN, a substrate receptor for the
CUL4A-DDB1 E3 ubiquitin ligase, a protein that employs an E2
ubiquitin-conjugating enzyme that carries ubiquitin, recognizes a
protein substrate, and assists the transfer of ubiquitin from the
E2 to the protein substrate. The ubiquitin is used to tag specific
proteins to be broken down by proteasomes. This binding inhibits the activity of the assembled E3 ubiquitin ligase complex
so that it does not tag the specific proteins, and an unknown
substrate is allowed to accumulate. This in turn effects the expression of the fibroblast growth factor eight (FGF8) and causes
growth defects. Thus, the action of the E3 ubiquitin ligase complex is necessary for limb outgrowth (particularly in zebrafish)
and by disrupting this complex, thalidomide induces teratogenic
effects. Consequently, they demonstrated that the deformities
caused by thalidomide were directly mediated through stopping
its inhibition of CRBN. In zebrafish and chickens, when they
used an overexpression of a CRBN mutant that does not bind
thalidomide, they did not notice the defects usually caused by
this drug, proving that it is the binding of the drug to CRBN that
is responsible for the embryopathy effect (Ito. et. al. 2010).
Following this discovery, CRBN was also shown to be crucial for the mechanism of action of thalidomide’s anti-myeloma
properties, as well as other immune-modulatory drugs (IMiDs).
One of the downstream targets of CRBN was shown to be interferon regulatory factor 4 (IRF4).This protein which regulates
the transcription of interferons is essential for myeloma cell
survival and is downregulated by IMiD therapy (Zhu, et. al. 2013).
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Figure 1. Depiction of the downstream targets of thalidomide that
may lead to its teratogenic properties (Zhu, et. al. 2013).
A recent series of experiments supported in part by the
National Cancer Institute further confirmed the hypothesis
that antiangiogenesis and teratogenesis are related. The researches tested a variety of angiogenesis inhibitors, including
thalidomide and its analog CPS49, using zebrafish and chicken
embryo models. They focused on assessing the developmental
defects and teratogenic effects that the drugs caused. They
concluded that different classes of angiogenesis inhibitors,
regardless of the molecular target or specific mechanism of
action, are teratogenic to chicken embryos. This study also
proved that using chicken embryos and zebrafish embryos is
a valid way to screen new drugs for teratogenic effects before
they are used in clinical trials on women of childbearing age
(Beedie, et. al. 2016).

New Research in Treatments Using Thalidomide
and Its Derivatives: Multiple Myeloma (MM)
Multiple Myeloma is a type of blood cancer that affects plasma
cells. In multiple myeloma, malignant plasma cells amass in the
bone marrow crowding out the normal plasma cells that help
fight infection. This disease can damage the bones, immune system, kidneys, and cause anemia. A randomized trial compared
the costs and benefits of using a melphalan (chemotherapy) and
prednisone (steroid) treatment in conjunction with thalidomide
(MPT) as opposed to melphalan and prednisone (MP) alone.The
testing was done on 135 elderly patients over the age of 65 with
MM who were ineligible for stem-cell transplants. The results
showed a significant increase in the median progression-free
survival (PFS) of patients using a combination of drugs that included thalidomide. PFS is the length of time during and after
the treatment of a disease that a patient lives with the disease
but it does not get worse. Also, the overall survival (OS) rate
was 52 months as opposed to only 32 months for patients using
only melphalan and prednisone. The following graph compares
the progression-free survival rate of patients using MPT versus
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MP treatment.The MPT group has a significantly higher PFS rate.
The Y axis is the fraction of living patients who began in the
study. Both the MPT and MP groups start at 1.00, meaning that
100% of participants are alive. The X axis is the months of the
treatment.The MPT group has a higher PFS rate during the forty
months of the trial. The P value is 0.02, meaning the results are
statistically significant (Sacchi, et. al. 2011).
One downside of adding thalidomide to the treatment regiment is the adverse side-effects that were more frequent in
patients using thalidomide, which will be discussed in more detail in the “Adverse Effects of Thalidomide” section of this paper.
Researchers observed a significant increase in neutropenia,
deep venous thrombosis, infection, and peripheral neuropathy.
The incidence of toxicity correlates with the drug dosage. The
study concluded that while including thalidomide in the therapy
showed an increase in activity against MM, it came with a substantial cost, which will be discussed later.
Trials have also been conducted using the second-generation
thalidomide derivate, lenalidomide. In a randomized, controlled
clinical trial, lenalidomide therapy (in combination with dexamethasone, a corticosteroid, or with melphalan and prednisone)
significantly improved PFS in patients with newly diagnosed MM
who were not eligible for stem-cell transplants as compared to
MP treatment alone. These improvements in progression-free
survival were also reflected in patients’ health-related quality of
life (McCormack, 2015).
In general, the analog was found to have improved efficacy and
increased tolerability as compared to thalidomide. Although the
treatment regiments had similar efficacy results, lenalidomide was
observed to have fewer toxic side-effects than its parent drug.The
continuous use of lenalidomide did not have a negative impact on
the drug’s tolerability. It also did not increase the cases of neutropenia as compared with shorter-term use of the drug. With new
analogs, melphalan and prednisone plus a thalidomide-type drug
could be considered the new standard of care for the treatment
of patients with MM over age 65 years and for younger patients
who are transplant-ineligible (McCormack, 2015).
Recent studies are working on understanding lenalidomide’s
mechanism of action. They propose that it affects signal transduction, also known as cell signaling, which leads to the suppression of COX-2 but not COX-1. This can partly explain its
selective efficacy on cells. Meaning, it is able to be more selective
in the cells it targets so it can have a greater potency with less
side effects. Even though the exact molecular targets of lenalidomide are not well known, its activity across a spectrum of
conditions highlights the possibility of multiple target sites of
action (Kotla, et. al. 2009).

Malignant Melanoma
Malignant melanoma is the most aggressive and life-threatening
skin cancer. It develops in the melanocytes and has a very high
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tendency to spread to other parts of the body. Symptoms can
include a new, unusual growth or a change in an existing mole.
Brain metastases will develop in almost half of the patients with
advanced melanoma and in 15-20% of these patients, the central
nervous system is the first site of relapse.The overall survival rate
is very short, only two to four months (Vestermark, et. al. 2008).
In one study, the antitumor activity and toxicity of thalidomide
was evaluated in patients with phase II brain metastases related
to metastatic melanoma. Thalidomide was administered orally
to patients, with the dose increasing over a one-month period
from 100 mg per day to 400 mg per day. Twenty-five men and
eleven women with a median age of forty-eight years were enrolled in the study.The average survival rate for the study group
was unchanged from historical data. Median PFS was 1.7 months
and OS was 3.1 months. Although thalidomide showed limited
activity against the metastatic melanoma in the central nervous
system, minor effects on peripheral tumor manifestation were
noted. This led researchers to conclude that thalidomide may
one day be part of the treatment plan for patients with that
form of metastasis in the future. Researchers also concluded
that more investigation should be done using thalidomide in
combination with Temozolomide, a cytotoxic chemotherapy
drug (Vestermark, et. al. 2008).

Persistent Erythema Multiforme
Erythema multiforme is a common, usually self-limited disease
which predominantly affects patients in their 20s and 30s. Its
symptoms include target shaped lesions (circular red patches
with central clearing) on the skin and mucous membranes.
There are three clinical subgroups of erythema multiforme:
classical, recurrent, and persistent erythema multiforme. The
most severe form is the persistent erythema multiforme
which can leave a patient stricken with continuous lesions. No
potential cause has been found yet, so this subgroup is defined
as idiopathic.
Thalidomide can be effectively used as a treatment for this
skin condition. It was initially introduced as a treatment for
persistent erythema multiforme as early as the 1980’s because
of its immunomodulatory and anti-inflammatory effects. The
following case report in the recent literature illustrates its
effectiveness. A fifteen-year-old boy in the Republic of China
experienced a sudden onset of target-like lesions on his trunk
and limbs. Although the wounds healed within two weeks, new
eruptions continued to appear. After unsuccessful treatment
attempts with oral corticosteroids and topical agents as well
as the antiviral drug valaciclovir, thalidomide was prescribed
to the patient. After two weeks of administering 100 mg per
day, the lesions gradually healed, and no new ones developed.
After two months of slowly reducing the dosage, there was no
recurrence of disorder. The researchers noted that because of
the risk of neuropathy associated with taking daily doses of this

medication, clinical vigilance and regular neurological exams are
advised (Chia-Wei, et. al. 2008).

Cutaneous Lupus Erythematosus (CLE)
Cutaneous Lupus Erythematosus is an autoimmune disease,
which affects multiple organ systems in the body. In this disease
an individual’s own immune system attacks various cells causing a
wide variety of symptoms.Typically, it causes extensive, disfiguring
lesions. Although these lesions are not life threatening, they can
be very itchy or painful. Many patients respond to standard treatment methods such as sunscreen, topical corticosteroids, or oral
antimalarial drugs. However, for cases in which these treatments
did not prove useful, or if the CLE was severe, thalidomide can be
an important therapeutic option (Sharma, et. al. 2007).
In a study done by the Department of Dermatology at the
University Hospital of Leuven, Belgium, thirty patients received
thalidomide treatment for refractory CLE over fifteen years
(from February 1998 to August 2013.) Each of these patients
had previously tried at least two different drug treatments
with no success. All of them were required to follow vigorous
contraceptive methods because of thalidomide’s known teratogenic properties. Patients received an initial dose of 50 mg per
day, which was increased to 100 mg if the CLE was extensive.
Although six patients prematurely stopped treatment due to
the negative side-effects, all patients who continued in the study
experienced improvements within 1-9 weeks after beginning
treatment. A high rate of relapse (73%) was observed in patients
who stopped thalidomide treatment. In addition, five patients
were not able to be weaned off the drug due to flare-ups of
CLE when they attempted to taper off the doses. The researchers concluded that while thalidomide treatment for CLE does
have strong efficacy, because of its considerable risk of polyneuropathy, it should only be considered as a possible therapy for
severe cases of CLE or for patients who have exhausted other
treatment options without significant relief (Baret, et. al. 2015).
In another study done on twenty-five patients in India suffering
from various inflammatory skin diseases, including discoid lupus
erythematosus, thalidomide was found to be an effective treatment. Of the seven patients with LE, four had excellent response,
two had partial response and one discontinued treatment due
to deep vein thrombosis (DVT). The authors recommended thalidomide as an effective treatment but advised physicians to be
watchful of thrombo-embolic events (Sharma, et. al. 2007).

Erythema Nodosum Leprosum (ENL)
When the author’s father, Stanley Newfield MD, was a young
dermatology resident training at the United States Public Health
Service Hospital in Staten Island, New York he was involved in
diagnosing and treating many cases of leprosy, also known as
Hansen’s disease. This research interest was perhaps especially
appropriate since he is a kohen, the traditional caretaker for
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people suffering from tzoras (leprosy) in the Torah.
As a federal institution, his hospital was responsible for caring for patients with transmissible infectious diseases. Leprosy
patients were referred from a large area of the north-eastern United States for treatment. One of the complications of
leprosy is the immune-system reaction known as Erythema
Nodosum Leprosum. ENL is characterized by the presence of
many inflammatory skin nodules and symptoms such as fever,
arthritis, eye inflammation, neuritis, and swollen lymph nodes. It
was observed that many patients suffered from ENL, which was
even more distressing to them than some of the other leprosy
symptoms such as loss of sensation in the extremities and/or
exaggerated skin folds on the face.
Dr. Newfield explained that he was surprised, back in 1979, to
find that the infamous drug, thalidomide, was the miraculously
effective treatment for ENL. He was well-aware of the teratogenic effects of the drug which he learned about in detail in
medical school. Now this same drug was resurrected for a new
use, albeit with strong precautions to avoid administration to
pregnant women. Due to his involvement in leprosy treatment,
he was coauthor of a research report on the epidemiology of
leprosy in New York City, which was published in the prestigious Journal of the American Medical Association.
Many people have a fear of leprosy since it is transmissible
through contact with an infected patient. However, this seems
to require prolonged exposure, usually in a household setting.
The research verified that very few leprosy patients acquire the
disease in the continental United States, rather they brought
the disease with them when they immigrated to this country.
The average latent period from entering the United States until
onset of symptoms was 4.8 years, with a range of 0 to 38 years
(Levis, et. al. 1982).
Almost forty years have passed since thalidomide was first
used for ENL treatment, and it remains the drug of choice for this
condition, as evidenced by two current research reports originating from India, a country with a large number of leprosy patients.
The first paper reports on eleven patients with ENL. Six of those
patients had excellent response to thalidomide and five had to
stop treatment prematurely due to side-effects (most commonly
DVT but also rashes and tremors.) (Sharma, et. al. 2007) In the
second study following one hundred patients diagnosed with
ENL, the group of fifty patients treated with thalidomide had a
faster and longer lasting clinical response than the control group
of fifty patients treated with prednisolone, a strong steroid medication. Patients on thalidomide also experienced fewer relapses
of their cutaneous symptoms (Kaur, et. al. 2009).

Animal Models of Alzheimer’s Disease (AD)
Alzheimer’s Disease is a degenerative disease that destroys
memory and other important mental functions. This is an incurable condition that afflicts an estimated 5.7 million people
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in the United States, mostly over the age of sixty-five. Research
studies are currently being performed on a mouse model of AD.
In one study, healthy mice were injected with streptozotocin
(STZ), a chemical that causes AD-like cognitive deficits. In this
study, one group of mice were pre-treated with thalidomide.
Learning and memory behaviors were evaluated on the seventeenth, eighteenth and nineteenth days of the study using the
Morris water maze test. In this test, a mouse is placed in the
center of a circular pool and must find the hidden platform that
allows it to escape. Mice that are not treated with the drug will
improve their time to escape after doing the test multiple times.
The SZT injections caused a significant decrease in the mice’s
improvement in their performance on the test. In comparison,
the learning and memory behaviors of the thalidomide treated
mice were significantly better preserved and they were able to
complete the tests with improved timing, although they were
not as improved as the mice who did not receive any drugs.
This positive result appears to be due to the anti-inflammatory
effect of TNF-alpha inhibition (Elçioğlu, et. al. 2013).
A second study used a strain of mice with the human
APPswedish transgenic (APP23) mutation. This mutation is associated with Alzheimer’s Disease. These mutated mice show
deficits in spatial memory which become severe with age. (The
Jackson Laboratory Website. 2018) This report showed that
thalidomide treatment improved memory and learning ability
in the mutated mice. The level of TNF-alpha in the thalidomide
treated mice was decreased.This in turn reduced the amount of
amyloid (A beta 1-42,) a harmful protein, which accumulated in
their brain tissue.The control group mice treated with the inactive vehicle had 750 units of harmful amyloid, while the thalidomide group had only approximately 100 units (He, et. al. 2013).
In mice brain tissue, the control group (treated with the vehicle) developed a large number of harmful senile plaques but the
thalidomide treated group showed very few.

Adverse Effects of Thalidomide
This section summarizes the adverse effects of thalidomide, some
of which have also been mentioned previously. Thalidomide was
withdrawn from widespread use shortly after the devastating
effects on developing embryos was discovered. The drug came
back into limited use for malignant and inflammatory diseases
in non-pregnant women. It can still have serious harmful effects:
peripheral neuropathy (pain and tingling in the hands and feet),
venous thrombosis (blood clots in the veins), skin rashes, constipation, somnolence (excessive daytime sleepiness), weakness, and
bradycardia (BC Cancer Drug Index. updated 2018).
Peripheral neuropathy is a common side effect that is associated with prolonged use of the drug, but there is no clear mechanism of action that explains its correlation with a cumulative
dose. The risk for nerve damage is highest after 6 months or
more of therapy. The symptoms are usually reversible when the
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patient stops thalidomide treatment, although some patients do
suffer long term nerve damage (Rajkumar, et. al. 2002).
Constipation caused by thalidomide can vary from mild to severe. As many as 90% of patients can develop mild constipation.
This effect is thought to be secondary to thalidomide’s action
on the autonomic nerve endings in the gut. Severe constipation
usually occurs in patients who are taking high doses of thalidomide. It is especially prevalent among patients who are already
prone to developing constipation, such as those who lead an
inactive lifestyle. Change of diet and exercise can help alleviate
this side effect (Hall, 2003).
Deep vein thrombosis and pulmonary embolisms only occur
in one to three percent of the patients receiving thalidomide
as treatment for myeloma. There is not enough research done
yet to determine whether the risk of DVT in these patients is
higher than usual for patients receiving other types of treatment
for this severe malignancy, due to the nature of the disease or
the side effect of immobility that it can cause. Patients confined
to bed rest tend to have higher rates of DVT. The risk is also
elevated when patients receive thalidomide treatment in combination with dexamethasone or other chemotherapy drugs, have
an inherited thrombotic predisposition, or are over the age of
sixty-five (Hall, 2003).
A recent case report documents a thirty-eight-year-old female from Puerto Rico with a history of prenatal thalidomide
exposure. She suffered from phocomelia, the dramatic birth
defect in which the hands or feet are attached close to the
trunk. An MRI scan revealed that the uterus and vagina were
also absent.These internal anomalies have been less appreciated
by physicians because they are not noticeable without special
imaging, however they can cause serious symptoms such as pain
and malignancy (Dotters-Katz, et. al. 2013).
The analog drug, lenalidomide, has not been found to be
teratogenic in rabbits, a sensitive species used to detect birth
defects. However, it may still have adverse effects such as morbilliform rashes (Huang, et. al. 2008). In a study done at Mount
Sinai Medical Center in New York City, doctors found that 7.2%
of the 806 patients receiving IMiD treatment developed rashes.
In almost all cases, the rashes could be managed without having to discontinue treatment. Thus, it appears that lenalidomide
may lack some of the adverse effects of thalidomide, while still
having superior immunomodulatory and antiangiogenic efficacy
than its parent drug (Barley, et. al. 2016).
An additional analog, Pomalidomide, is now an approved
drug for MM. A research study conducted in Aberdeen, United
Kingdom analyzed its effect on zebrafish and chicken embryos.
The tests showed no detectable teratogenic, antiangiogenic or
neurotoxic effects. Despite having less side effects, it has more
anti-inflammatory properties than either thalidomide or lenalidomide (Mahony, et. al. 2013).

Conclusion
The psalmist wrote, “The stone that the builders rejected became
a cornerstone.” (Psalm 118:22) This report illustrates this concept
as it pertains to the drug, thalidomide. This drug was universally
banned due to its harmful side-effects. Years later it was found to
have unique healing properties in several serious diseases.
It appears that the continued use and development of thalidomide treatments is justified. Although it can have many serious
side effects, specifically crippling teratogenesis, it is often the
last resort as treatment for patients suffering serious diseases.
Care should be taken to prevent pregnant women from using
this drug to avoid causing birth defects. Given the significance of
these effects, the future of thalidomide is not in the drug itself
but in the derivatives that are now being tested. Lenalidomide
and pomalidomide are more effective and have less toxic effects.
As scientists continue to discover their specific mechanisms of
action they will be able to alter the drug to have even less adverse effects and help more patients worldwide. The prognosis
for PFS and OS for patients with MM and other forms of cancer will decrease even more and give the people suffering with
these diseases hope for their future. With this new and exciting
research thalidomide and its analogs have justly become important medical treatments.
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